Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system that
involves demyelination and axonal degeneration. Although substantial progress has been …

A major therapeutic goal in the treatment of multiple sclerosis (MS) is to prevent the
accumulation of disability over an often decades-long disease course. Disability progression …

Receptor interacting protein kinase 1 (RIPK1) mediates cell death and inflammatory
signaling and is increased in multiple sclerosis (MS) brain samples. Here, we investigate the …

Background Fatigue is a complex and disabling symptom of Multiple Sclerosis (MS);
however, there is conflicting evidence of the relationship between fatigue and clinical …

Background and Objective To explore the relationship between slowly expanding lesions
(SELs) on MRI and disability in secondary progressive multiple sclerosis (SPMS). Methods …

Multiple sclerosis is an immune-mediated chronic inflammatory disease of the CNS that
leads to demyelinated lesions in the grey and white matter. Inflammatory, active …

Microglia harness an unutilized health-promoting potential in age-related
neurodegenerative and neuroinflammatory diseases, conditions like progressive multiple …

Background and Objectives Ocrelizumab improved clinical and MRI measures of disease
activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses …

Myeloid cells contribute to inflammation and demyelination in the early stages of multiple
sclerosis (MS), but it is still unclear to what extent these cells are involved in active lesion …

Multiple sclerosis (MS) is primarily an inflammatory and degenerative disease of the central
nervous system, triggered by unknown environmental factors in patients with predisposing …